Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLCW. Marston Linehan, Gregory J. Riely, Ashish Saxena et al.|Journal of Thoracic Oncology|2018Cited by 82
MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or ChemotherapyKai He, Ticiana Leal, David Berz et al.|Journal of Thoracic Oncology|2023Cited by 38